Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanming Zhang

Showing results (421-430 of 459) with videos related to

Pageof 46
Sort By:
NPJ Digital Medicine|May 3, 2025
Multimodal GPT model for assisting thyroid nodule diagnosis and managementJincao Yao, Yunpeng Wang, Zhikai Lei, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001Francesco Maura, Benjamin Diamond, Kylee H Maclachlan, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2019
JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical managementSounak Gupta, John C Cheville, Achim A Jungbluth, et al.
Nature Communications|March 26, 2021
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entitiesBénedith Oben, Guy Froyen, Kylee H Maclachlan, et al.
Acta Neuropathologica|May 17, 2024
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumorsAndrew L Lin, Vasilisa A Rudneva, Allison L Richards, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Blood Cancer Discovery|January 4, 2021
Revealing the impact of structural variants in multiple myelomaEven H Rustad, Venkata D Yellapantula, Dominik Glodzik, et al.
Pageof 46

Showing results (421-430 of 459) with videos related to

Sort By:
Pageof 46
NPJ Digital Medicine|May 3, 2025
Multimodal GPT model for assisting thyroid nodule diagnosis and managementJincao Yao, Yunpeng Wang, Zhikai Lei, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001Francesco Maura, Benjamin Diamond, Kylee H Maclachlan, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2019
JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical managementSounak Gupta, John C Cheville, Achim A Jungbluth, et al.
Nature Communications|March 26, 2021
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entitiesBénedith Oben, Guy Froyen, Kylee H Maclachlan, et al.
Acta Neuropathologica|May 17, 2024
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumorsAndrew L Lin, Vasilisa A Rudneva, Allison L Richards, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Blood Cancer Discovery|January 4, 2021
Revealing the impact of structural variants in multiple myelomaEven H Rustad, Venkata D Yellapantula, Dominik Glodzik, et al.
Pageof 46